Blood Viscometer Market Size

Blood Viscometer Market size was valued at USD 1.84 billion in 2025 and is set to exceed USD 2.78 billion by 2035, registering over 4.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of blood viscometer is estimated at USD 1.91 billion.

The rising patient pool with blood disorders is propelling the need for blood viscometers. Presently, 33,000 males suffer from hemophilia in the U.S., while a large base of children also develop the disease by the age of two. 69.7% with genetic predisposition develop the condition within 1 month and 2.8% get it in the prenatal stage. Individuals with the condition are living longer and have fewer complications, owing to NCBDDD data of 74,000 patients at over 140 hemophilia treatment centers in the U.S. The government and other institutional bodies work in close collaboration to promote healthcare facilities and reduce inequities among patients.

NCBDDD Budget Allocation, in 2023

Source: CDC

Furthermore, the CDC, NCBDDD has an upcoming discretionary grant for promoting self-management to mitigate blood disorder community and related mortality using evidence-based programs, commencing September 2025. The program funding is estimated at USD 3,555,000, with an award floor of USD 150,000 and an award ceiling of USD 450,000. In terms of patient care and benefits, before obtaining care, consumers can better understand the cost of a covered good or service thanks to health plan price transparency. Pricing information for covered goods and services is being posted by the majority of group health plans and individual or group health insurance issuers as of July 1, 2022. Third parties, such as academics and app developers, can utilize this pricing information to assist consumers in better understanding the costs of their medical treatment.

HRSA allocated USD 52 million for cell transplantation and cord blood stem cell bank systems, whereas the NIH funded the National Heart, Lung, and Blood Institute with USD 3,985 million in 2024. To drive accessibility of blood disorder treatment and other healthcare services, the Centers for Medicare & Medicaid Services (CMS) has set hospital price transparency under the Public Health Service Act. Similarly, in July 2024 CMS issued a proposed rule that solicits public comments as part of the Physician Fee Schedule (PFS) on proposed policy changes for Medicare payments. Reporting for Value in Primary Care MIPS Value Pathway (MVP) would begin in 2026 based on the calendar year 2025 performance. 

Pricing Comparison of Blood Disorder Treatments (2024)

Source: Medicaid